WuXi AppTec Co., Ltd. Share Price

Equities

603259

CNE1000031K4

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. 23:00:00 23/06/2024 BST 5-day change 1st Jan Change
40.42 CNY -0.17% Intraday chart for WuXi AppTec Co., Ltd. -8.07% -44.45%

Financials

Sales 2024 * 39.55B 5.45B 430B Sales 2025 * 43.81B 6.04B 476B Capitalization 113B 15.57B 1,227B
Net income 2024 * 9.69B 1.34B 105B Net income 2025 * 10.93B 1.51B 119B EV / Sales 2024 * 2.6 x
Net cash position 2024 * 10.04B 1.38B 109B Net cash position 2025 * 15.82B 2.18B 172B EV / Sales 2025 * 2.22 x
P/E ratio 2024 *
12.1 x
P/E ratio 2025 *
10.8 x
Employees 41,116
Yield 2024 *
2.48%
Yield 2025 *
2.54%
Free-Float 66.39%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.17%
1 week-8.07%
Current month-4.01%
1 month-5.45%
3 months-15.63%
6 months-44.27%
Current year-44.45%
More quotes
1 week
39.88
Extreme 39.88
42.59
1 month
39.88
Extreme 39.88
46.12
Current year
39.88
Extreme 39.88
75.38
1 year
39.88
Extreme 39.88
93.56
3 years
39.88
Extreme 39.88
172.49
5 years
35.21
Extreme 35.2126
172.49
10 years
11.02
Extreme 11.0204
172.49
More quotes
Managers TitleAgeSince
Founder 54 30/11/00
Chief Executive Officer 56 30/11/00
Chief Executive Officer 55 30/11/15
Members of the board TitleAgeSince
Chief Investment Officer 61 31/12/06
Director/Board Member 50 22/03/16
Chief Executive Officer 56 30/11/00
More insiders
Date Price Change Volume
24/06/24 40.42 -0.17% 37,079,050
21/06/24 40.49 -1.46% 42,664,120
20/06/24 41.09 -2.03% 59,777,540
19/06/24 41.94 -1.39% 46,952,330
18/06/24 42.53 -3.27% 77,222,710

End-of-day quote Shanghai S.E., June 23, 2024

More quotes
WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows: - laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.; - CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.; - clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.; - other (0.1%). Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
40.42 CNY
Average target price
68.33 CNY
Spread / Average Target
+69.06%
Consensus
  1. Stock Market
  2. Equities
  3. 603259 Stock